Pancreatic Cancer Research

Clinical trialPhase 2Unknown

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

An Exploratory Study to Evaluate Radiotherapy Combined With Irinotecan Liposome and Apatinib Followed by PD-1 Antibody and Apatinib for the Treatment of Advanced Solid Tumors That Failed Standard Treatments

Outcome
Outcome unknown
Phase
Phase 2
Status
Unknown
Study type
Interventional
Start
September 2020
Listed end
May 2023
Enrollment
30 participants
Sites
1
Primary outcomes
Objective Response Rate
Sponsor type
Academic / other
Results posted
No
Last update
30 September 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.

Detailed description public domain (ClinicalTrials.gov)

This is a prospective, single-arm, observational study. After the subjects meet the inclusive and exclusive criteria, then they will receive radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib.